ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Structure-Based Identification of Jervine as a Potent Dual-Targeting Inhibitor of Cell Cycle Kinases
Provisionally accepted
Md Nayab Sulaimani1
Khadija Imtiyaz1
Imtaiyaz Hassan1
Fohad Mabood Husain2Aanchal Rathi1Mir Ovais Farooq3Anam Ashraf1
Ravins Dohare1
Saba Noor1*- 1Jamia Millia Islamia, New Delhi, India
- 2King Saud University, Riyadh, Saudi Arabia
- 3Central University of Kashmir, Ganderbal, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Mitotic regulators play an essential role in cell cycle progression by ensuring correct chromosomal alignment, segregation, DNA replication, repair, and division, thereby maintaining genomic stability. Aberrant activity of cell cycle kinases, including aurora kinase B (AURKB) and cyclin-dependent kinase 1 (CDK1), might lead to disrupted mitotic checkpoints, causing aneuploidies and uncontrolled proliferation, which are critical hallmarks of cancers. Targeted inhibition of cell cycle kinases is an attractive strategy to combat cancers with minimal side effects. This study employed a comprehensive multi-staged computational approach to discover dual-targeting inhibitors against AURKB and CDK1, which are reported as key promoters of tumorigenesis. High-throughput screening of phytochemicals available in the Indian Medicinal Plants, Phytochemistry, and Therapeutics (IMPPAT) database was conducted to identify common lead/s from top hits. Jervine (IMPHY000366), a steroid alkaloid, emerged as a common compound depicting high binding affinity and ligand efficiency for AURKB and CDK1. In addition, this compound qualified all drug-like filters. After structure analysis, the docked complex was subjected to 300 ns MD simulation studies, confirming structural integrity in AURKB and CDK1 upon binding of Jervine. H-bonding pattern, secondary structural content, free energy landscape, and principal component analysis further supported Jervine's strong and stable affinity for AURKB and CDK1. Lastly, MMPBSA showed a higher negative free energy in the presence of Jervine than VX-680 when complexed with AURKB. Finally, our results suggest that Jervine is a potent, dual-targeting kinase inhibitor with favourable pharmacokinetic and therapeutic properties, warranting further experimental validation for anticancer drug development.
Keywords: Aurora Kinase B, Cyclin-dependent kinase 1, Drug Discovery, High-Throughput Screening, MD simulation, kinase inhibitors, Natural Products
Received: 09 Jul 2025; Accepted: 28 Oct 2025.
Copyright: © 2025 Sulaimani, Imtiyaz, Hassan, Husain, Rathi, Farooq, Ashraf, Dohare and Noor. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Saba Noor, sabanooramu@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.